In the BioHarmony Drug Report Database

"Preview" Icon

Selegiline

Emsam (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Emsam on 2006-02-27. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.

 

Trade Name

 

Emsam
 

Common Name

 

selegiline
 

ChEMBL ID

 

CHEMBL972
 

Indication

 

alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, schizophrenia
 

Drug Class

 

Mao inhibitors, type B

Image (chem structure or protein)

Selegiline structure rendering